Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting

Prajwal BodduDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA;

Abdul Rashid ShahDepartment of Hematology and Oncology, Moffitt Cancer Center, Tampa, FL, USA; View further author information

Gautam BorthakurDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA;

Srdan VerstovsekDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Guillermo Garcia-ManeroDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Naval DaverDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Tapan KadiaDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Farhad RavandiDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Nitin JainDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Ahmad AlhuraijiDepartment of Hematology, Kuwait Cancer Center, Shuwaikh, KuwaitView further author information

Jan BurgerDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Steven KornblauDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Sherry PierceDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Sara DellasalaDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Elias JabbourDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Hagop KantarjianDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information

Jorge CortesDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Correspondence[email protected]
View further author information

Articles from other publishers (8)